Mirae Asset Global Etfs Holdings Ltd. C4 Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $39.6 Billion
- Q2 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 6,993 shares of CCCC stock, worth $42,377. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,993Holding current value
$42,377% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
129Shares Held
54MCall Options Held
331KPut Options Held
145K-
Ra Capital Management, L.P. Boston, MA4.88MShares$29.6 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$29.4 Million0.12% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$27.6 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.05MShares$24.6 Million1.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.56MShares$21.6 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $296M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...